Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Pharma (@PumaPharma) / Twitter
Puma Biotechnology: Nerlynx Peak Sales Estimates Have Come Down, But The Intense Selling Still Makes This A Buy (NASDAQ:PBYI) | Seeking Alpha
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug - TheStreet
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology
Puma Biotechnology Releases Updated Corporate Presentation | Business Wire
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotech punts near $300 million on Takeda discard
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
Pierre Fabre étend sa collaboration avec Puma Biotechnology
Exhibitor Puma Biotechnology 11-6 - Scripps CME Connection
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology
Puma Biotechnology: Too Little, Too Late, Too Much Of A Bad Side Effect (NASDAQ:PBYI) | Seeking Alpha
Is Puma Biotechnology Inc (PBYI) a Leader in the Healthcare Sector?
Fillable Online Puma biotechnology, inc. form s-1/a - Biotech Due Diligence Fax Email Print - pdfFiller
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Here's Why The Puma Biotechnology Inc (NYSE:PBYI) Pullback Might Be A Buy-In Opportunity - Market Exclusive
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Auerbach, Yancopoulos To Speak At Forbes Healthcare Summit
Puma Biotechnology - Crunchbase Company Profile & Funding
